Published in Blood Weekly, March 17th, 1997
Selective patients with hematologic malignancies (e.g., multiple myeloma) have been cured by allogeneic bone marrow transplantations. A large portion of this procedure's curative potential depends on an antitumor effect derived from the adoptive transfer of immunocompetent cells present in the donor graft, also known as GVL.
Unfortunately, the same cells that stimulate this GVL effect are also responsible for GVHD....
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.